nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR6—Raloxifene—osteoporosis	0.292	0.577	CbGbCtD
Duloxetine—CYP1A2—Estropipate—osteoporosis	0.0927	0.183	CbGbCtD
Duloxetine—CYP1A2—Conjugated Estrogens—osteoporosis	0.0439	0.0865	CbGbCtD
Duloxetine—CYP2D6—Cholecalciferol—osteoporosis	0.0394	0.0776	CbGbCtD
Duloxetine—CYP1A2—Estradiol—osteoporosis	0.0385	0.076	CbGbCtD
Duloxetine—Cough—Conjugated Estrogens—osteoporosis	0.000238	0.000552	CcSEcCtD
Duloxetine—Erythema multiforme—Estradiol—osteoporosis	0.000237	0.00055	CcSEcCtD
Duloxetine—Convulsion—Conjugated Estrogens—osteoporosis	0.000237	0.000548	CcSEcCtD
Duloxetine—Dry mouth—Zoledronate—osteoporosis	0.000236	0.000547	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000236	0.000546	CcSEcCtD
Duloxetine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000236	0.000546	CcSEcCtD
Duloxetine—Pruritus—Alendronate—osteoporosis	0.000235	0.000544	CcSEcCtD
Duloxetine—Dyspepsia—Risedronate—osteoporosis	0.000235	0.000543	CcSEcCtD
Duloxetine—Eye disorder—Estradiol—osteoporosis	0.000235	0.000543	CcSEcCtD
Duloxetine—Tinnitus—Estradiol—osteoporosis	0.000234	0.000542	CcSEcCtD
Duloxetine—Constipation—Ethinyl Estradiol—osteoporosis	0.000234	0.000541	CcSEcCtD
Duloxetine—Confusional state—Zoledronate—osteoporosis	0.000233	0.00054	CcSEcCtD
Duloxetine—Hypersensitivity—Calcitriol—osteoporosis	0.000233	0.00054	CcSEcCtD
Duloxetine—Flushing—Estradiol—osteoporosis	0.000233	0.000539	CcSEcCtD
Duloxetine—Cardiac disorder—Estradiol—osteoporosis	0.000233	0.000539	CcSEcCtD
Duloxetine—Myalgia—Conjugated Estrogens—osteoporosis	0.000233	0.000538	CcSEcCtD
Duloxetine—Chest pain—Conjugated Estrogens—osteoporosis	0.000233	0.000538	CcSEcCtD
Duloxetine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000233	0.000538	CcSEcCtD
Duloxetine—Asthenia—Ibandronate—osteoporosis	0.000232	0.000537	CcSEcCtD
Duloxetine—Anxiety—Conjugated Estrogens—osteoporosis	0.000232	0.000536	CcSEcCtD
Duloxetine—Nausea—Etidronic acid—osteoporosis	0.000232	0.000536	CcSEcCtD
Duloxetine—Anaphylactic shock—Zoledronate—osteoporosis	0.000231	0.000536	CcSEcCtD
Duloxetine—Oedema—Zoledronate—osteoporosis	0.000231	0.000536	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000231	0.000535	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000231	0.000535	CcSEcCtD
Duloxetine—Diarrhoea—Estropipate—osteoporosis	0.000231	0.000534	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00023	0.000533	CcSEcCtD
Duloxetine—Infection—Zoledronate—osteoporosis	0.00023	0.000532	CcSEcCtD
Duloxetine—Fatigue—Risedronate—osteoporosis	0.00023	0.000532	CcSEcCtD
Duloxetine—Insomnia—Pamidronate—osteoporosis	0.000229	0.000531	CcSEcCtD
Duloxetine—Pruritus—Ibandronate—osteoporosis	0.000229	0.00053	CcSEcCtD
Duloxetine—Pain—Risedronate—osteoporosis	0.000228	0.000528	CcSEcCtD
Duloxetine—Constipation—Risedronate—osteoporosis	0.000228	0.000528	CcSEcCtD
Duloxetine—Angiopathy—Estradiol—osteoporosis	0.000228	0.000527	CcSEcCtD
Duloxetine—Shock—Zoledronate—osteoporosis	0.000228	0.000527	CcSEcCtD
Duloxetine—Paraesthesia—Pamidronate—osteoporosis	0.000228	0.000527	CcSEcCtD
Duloxetine—Diarrhoea—Alendronate—osteoporosis	0.000227	0.000526	CcSEcCtD
Duloxetine—Asthenia—Calcitriol—osteoporosis	0.000227	0.000526	CcSEcCtD
Duloxetine—Nervous system disorder—Zoledronate—osteoporosis	0.000227	0.000526	CcSEcCtD
Duloxetine—Immune system disorder—Estradiol—osteoporosis	0.000227	0.000525	CcSEcCtD
Duloxetine—Thrombocytopenia—Zoledronate—osteoporosis	0.000227	0.000525	CcSEcCtD
Duloxetine—Mediastinal disorder—Estradiol—osteoporosis	0.000226	0.000524	CcSEcCtD
Duloxetine—Tachycardia—Zoledronate—osteoporosis	0.000226	0.000523	CcSEcCtD
Duloxetine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000225	0.000522	CcSEcCtD
Duloxetine—Chills—Estradiol—osteoporosis	0.000225	0.000522	CcSEcCtD
Duloxetine—Somnolence—Pamidronate—osteoporosis	0.000225	0.000522	CcSEcCtD
Duloxetine—Skin disorder—Zoledronate—osteoporosis	0.000225	0.000521	CcSEcCtD
Duloxetine—Pruritus—Calcitriol—osteoporosis	0.000224	0.000519	CcSEcCtD
Duloxetine—Hyperhidrosis—Zoledronate—osteoporosis	0.000224	0.000518	CcSEcCtD
Duloxetine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000224	0.000518	CcSEcCtD
Duloxetine—Diarrhoea—Raloxifene—osteoporosis	0.000224	0.000518	CcSEcCtD
Duloxetine—Dyspepsia—Pamidronate—osteoporosis	0.000223	0.000516	CcSEcCtD
Duloxetine—Dizziness—Estropipate—osteoporosis	0.000223	0.000516	CcSEcCtD
Duloxetine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000223	0.000516	CcSEcCtD
Duloxetine—Oedema—Conjugated Estrogens—osteoporosis	0.000223	0.000516	CcSEcCtD
Duloxetine—Alopecia—Estradiol—osteoporosis	0.000222	0.000514	CcSEcCtD
Duloxetine—Infection—Conjugated Estrogens—osteoporosis	0.000221	0.000513	CcSEcCtD
Duloxetine—Diarrhoea—Ibandronate—osteoporosis	0.000221	0.000512	CcSEcCtD
Duloxetine—Anorexia—Zoledronate—osteoporosis	0.000221	0.000511	CcSEcCtD
Duloxetine—Decreased appetite—Pamidronate—osteoporosis	0.00022	0.00051	CcSEcCtD
Duloxetine—Mental disorder—Estradiol—osteoporosis	0.00022	0.000509	CcSEcCtD
Duloxetine—Dizziness—Alendronate—osteoporosis	0.00022	0.000509	CcSEcCtD
Duloxetine—Shock—Conjugated Estrogens—osteoporosis	0.000219	0.000508	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000219	0.000507	CcSEcCtD
Duloxetine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000219	0.000506	CcSEcCtD
Duloxetine—Erythema—Estradiol—osteoporosis	0.000219	0.000506	CcSEcCtD
Duloxetine—Malnutrition—Estradiol—osteoporosis	0.000219	0.000506	CcSEcCtD
Duloxetine—Fatigue—Pamidronate—osteoporosis	0.000218	0.000506	CcSEcCtD
Duloxetine—Gastrointestinal pain—Risedronate—osteoporosis	0.000218	0.000505	CcSEcCtD
Duloxetine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000218	0.000504	CcSEcCtD
Duloxetine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000217	0.000503	CcSEcCtD
Duloxetine—Constipation—Pamidronate—osteoporosis	0.000217	0.000502	CcSEcCtD
Duloxetine—Pain—Pamidronate—osteoporosis	0.000217	0.000502	CcSEcCtD
Duloxetine—Diarrhoea—Calcitriol—osteoporosis	0.000217	0.000502	CcSEcCtD
Duloxetine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000217	0.000501	CcSEcCtD
Duloxetine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000216	0.0005	CcSEcCtD
Duloxetine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000216	0.0005	CcSEcCtD
Duloxetine—Dizziness—Raloxifene—osteoporosis	0.000216	0.0005	CcSEcCtD
Duloxetine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000215	0.000499	CcSEcCtD
Duloxetine—Flatulence—Estradiol—osteoporosis	0.000215	0.000499	CcSEcCtD
Duloxetine—Tension—Estradiol—osteoporosis	0.000214	0.000497	CcSEcCtD
Duloxetine—Vomiting—Estropipate—osteoporosis	0.000214	0.000497	CcSEcCtD
Duloxetine—Dysgeusia—Estradiol—osteoporosis	0.000214	0.000496	CcSEcCtD
Duloxetine—Dizziness—Ibandronate—osteoporosis	0.000214	0.000495	CcSEcCtD
Duloxetine—Rash—Estropipate—osteoporosis	0.000213	0.000492	CcSEcCtD
Duloxetine—Dermatitis—Estropipate—osteoporosis	0.000212	0.000492	CcSEcCtD
Duloxetine—Anorexia—Conjugated Estrogens—osteoporosis	0.000212	0.000492	CcSEcCtD
Duloxetine—Nervousness—Estradiol—osteoporosis	0.000212	0.000491	CcSEcCtD
Duloxetine—Urticaria—Risedronate—osteoporosis	0.000212	0.00049	CcSEcCtD
Duloxetine—Back pain—Estradiol—osteoporosis	0.000211	0.000489	CcSEcCtD
Duloxetine—Headache—Estropipate—osteoporosis	0.000211	0.000489	CcSEcCtD
Duloxetine—Vomiting—Alendronate—osteoporosis	0.000211	0.000489	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000211	0.000488	CcSEcCtD
Duloxetine—Body temperature increased—Risedronate—osteoporosis	0.000211	0.000488	CcSEcCtD
Duloxetine—Abdominal pain—Risedronate—osteoporosis	0.000211	0.000488	CcSEcCtD
Duloxetine—Muscle spasms—Estradiol—osteoporosis	0.00021	0.000487	CcSEcCtD
Duloxetine—Rash—Alendronate—osteoporosis	0.000209	0.000485	CcSEcCtD
Duloxetine—Insomnia—Zoledronate—osteoporosis	0.000209	0.000485	CcSEcCtD
Duloxetine—Dermatitis—Alendronate—osteoporosis	0.000209	0.000485	CcSEcCtD
Duloxetine—Feeling abnormal—Pamidronate—osteoporosis	0.000209	0.000483	CcSEcCtD
Duloxetine—Headache—Alendronate—osteoporosis	0.000208	0.000482	CcSEcCtD
Duloxetine—Paraesthesia—Zoledronate—osteoporosis	0.000208	0.000481	CcSEcCtD
Duloxetine—Vomiting—Raloxifene—osteoporosis	0.000208	0.000481	CcSEcCtD
Duloxetine—Gastrointestinal pain—Pamidronate—osteoporosis	0.000207	0.00048	CcSEcCtD
Duloxetine—Rash—Raloxifene—osteoporosis	0.000206	0.000477	CcSEcCtD
Duloxetine—Dermatitis—Raloxifene—osteoporosis	0.000206	0.000477	CcSEcCtD
Duloxetine—Somnolence—Zoledronate—osteoporosis	0.000206	0.000476	CcSEcCtD
Duloxetine—Vomiting—Ibandronate—osteoporosis	0.000206	0.000476	CcSEcCtD
Duloxetine—Tremor—Estradiol—osteoporosis	0.000205	0.000474	CcSEcCtD
Duloxetine—Headache—Raloxifene—osteoporosis	0.000205	0.000474	CcSEcCtD
Duloxetine—Rash—Ibandronate—osteoporosis	0.000204	0.000472	CcSEcCtD
Duloxetine—Dermatitis—Ibandronate—osteoporosis	0.000204	0.000472	CcSEcCtD
Duloxetine—Dyspepsia—Zoledronate—osteoporosis	0.000204	0.000472	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000203	0.00047	CcSEcCtD
Duloxetine—Ill-defined disorder—Estradiol—osteoporosis	0.000203	0.00047	CcSEcCtD
Duloxetine—Headache—Ibandronate—osteoporosis	0.000203	0.000469	CcSEcCtD
Duloxetine—Insomnia—Conjugated Estrogens—osteoporosis	0.000202	0.000467	CcSEcCtD
Duloxetine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000201	0.000466	CcSEcCtD
Duloxetine—Vomiting—Calcitriol—osteoporosis	0.000201	0.000466	CcSEcCtD
Duloxetine—Decreased appetite—Zoledronate—osteoporosis	0.000201	0.000466	CcSEcCtD
Duloxetine—Agitation—Estradiol—osteoporosis	0.000201	0.000465	CcSEcCtD
Duloxetine—Nausea—Estropipate—osteoporosis	0.0002	0.000464	CcSEcCtD
Duloxetine—Abdominal pain—Pamidronate—osteoporosis	0.0002	0.000464	CcSEcCtD
Duloxetine—Body temperature increased—Pamidronate—osteoporosis	0.0002	0.000464	CcSEcCtD
Duloxetine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.0002	0.000463	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Zoledronate—osteoporosis	0.0002	0.000463	CcSEcCtD
Duloxetine—Angioedema—Estradiol—osteoporosis	0.0002	0.000462	CcSEcCtD
Duloxetine—Rash—Calcitriol—osteoporosis	0.0002	0.000462	CcSEcCtD
Duloxetine—Fatigue—Zoledronate—osteoporosis	0.0002	0.000462	CcSEcCtD
Duloxetine—Dermatitis—Calcitriol—osteoporosis	0.000199	0.000462	CcSEcCtD
Duloxetine—Headache—Calcitriol—osteoporosis	0.000198	0.000459	CcSEcCtD
Duloxetine—Somnolence—Conjugated Estrogens—osteoporosis	0.000198	0.000459	CcSEcCtD
Duloxetine—Pain—Zoledronate—osteoporosis	0.000198	0.000458	CcSEcCtD
Duloxetine—Constipation—Zoledronate—osteoporosis	0.000198	0.000458	CcSEcCtD
Duloxetine—Nausea—Alendronate—osteoporosis	0.000197	0.000457	CcSEcCtD
Duloxetine—Malaise—Estradiol—osteoporosis	0.000197	0.000456	CcSEcCtD
Duloxetine—Hypersensitivity—Risedronate—osteoporosis	0.000196	0.000455	CcSEcCtD
Duloxetine—Vertigo—Estradiol—osteoporosis	0.000196	0.000455	CcSEcCtD
Duloxetine—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000196	0.000454	CcSEcCtD
Duloxetine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000196	0.000454	CcSEcCtD
Duloxetine—Syncope—Estradiol—osteoporosis	0.000196	0.000454	CcSEcCtD
Duloxetine—Nausea—Raloxifene—osteoporosis	0.000194	0.000449	CcSEcCtD
Duloxetine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000194	0.000449	CcSEcCtD
Duloxetine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000193	0.000448	CcSEcCtD
Duloxetine—Palpitations—Estradiol—osteoporosis	0.000193	0.000447	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000192	0.000445	CcSEcCtD
Duloxetine—Fatigue—Conjugated Estrogens—osteoporosis	0.000192	0.000445	CcSEcCtD
Duloxetine—Nausea—Ibandronate—osteoporosis	0.000192	0.000445	CcSEcCtD
Duloxetine—Loss of consciousness—Estradiol—osteoporosis	0.000192	0.000445	CcSEcCtD
Duloxetine—Asthenia—Risedronate—osteoporosis	0.000191	0.000443	CcSEcCtD
Duloxetine—Feeling abnormal—Zoledronate—osteoporosis	0.000191	0.000442	CcSEcCtD
Duloxetine—Cough—Estradiol—osteoporosis	0.000191	0.000442	CcSEcCtD
Duloxetine—Pain—Conjugated Estrogens—osteoporosis	0.000191	0.000441	CcSEcCtD
Duloxetine—Constipation—Conjugated Estrogens—osteoporosis	0.000191	0.000441	CcSEcCtD
Duloxetine—Gastrointestinal pain—Zoledronate—osteoporosis	0.000189	0.000438	CcSEcCtD
Duloxetine—Hypertension—Estradiol—osteoporosis	0.000189	0.000437	CcSEcCtD
Duloxetine—Pruritus—Risedronate—osteoporosis	0.000189	0.000437	CcSEcCtD
Duloxetine—Nausea—Calcitriol—osteoporosis	0.000188	0.000435	CcSEcCtD
Duloxetine—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000187	0.000433	CcSEcCtD
Duloxetine—Hypersensitivity—Pamidronate—osteoporosis	0.000187	0.000432	CcSEcCtD
Duloxetine—Chest pain—Estradiol—osteoporosis	0.000186	0.000431	CcSEcCtD
Duloxetine—Arthralgia—Estradiol—osteoporosis	0.000186	0.000431	CcSEcCtD
Duloxetine—Myalgia—Estradiol—osteoporosis	0.000186	0.000431	CcSEcCtD
Duloxetine—Anxiety—Estradiol—osteoporosis	0.000185	0.000429	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000185	0.000428	CcSEcCtD
Duloxetine—Urticaria—Zoledronate—osteoporosis	0.000184	0.000426	CcSEcCtD
Duloxetine—Discomfort—Estradiol—osteoporosis	0.000184	0.000426	CcSEcCtD
Duloxetine—Abdominal pain—Zoledronate—osteoporosis	0.000183	0.000424	CcSEcCtD
Duloxetine—Body temperature increased—Zoledronate—osteoporosis	0.000183	0.000424	CcSEcCtD
Duloxetine—Diarrhoea—Risedronate—osteoporosis	0.000182	0.000422	CcSEcCtD
Duloxetine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000182	0.000422	CcSEcCtD
Duloxetine—Dry mouth—Estradiol—osteoporosis	0.000182	0.000421	CcSEcCtD
Duloxetine—Asthenia—Pamidronate—osteoporosis	0.000182	0.000421	CcSEcCtD
Duloxetine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000181	0.000419	CcSEcCtD
Duloxetine—Confusional state—Estradiol—osteoporosis	0.00018	0.000416	CcSEcCtD
Duloxetine—Pruritus—Pamidronate—osteoporosis	0.000179	0.000415	CcSEcCtD
Duloxetine—Oedema—Estradiol—osteoporosis	0.000178	0.000413	CcSEcCtD
Duloxetine—Anaphylactic shock—Estradiol—osteoporosis	0.000178	0.000413	CcSEcCtD
Duloxetine—Infection—Estradiol—osteoporosis	0.000177	0.00041	CcSEcCtD
Duloxetine—Urticaria—Conjugated Estrogens—osteoporosis	0.000177	0.00041	CcSEcCtD
Duloxetine—Dizziness—Risedronate—osteoporosis	0.000176	0.000408	CcSEcCtD
Duloxetine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000176	0.000408	CcSEcCtD
Duloxetine—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000176	0.000408	CcSEcCtD
Duloxetine—Shock—Estradiol—osteoporosis	0.000176	0.000406	CcSEcCtD
Duloxetine—Nervous system disorder—Estradiol—osteoporosis	0.000175	0.000405	CcSEcCtD
Duloxetine—Tachycardia—Estradiol—osteoporosis	0.000174	0.000403	CcSEcCtD
Duloxetine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000174	0.000402	CcSEcCtD
Duloxetine—Diarrhoea—Pamidronate—osteoporosis	0.000173	0.000401	CcSEcCtD
Duloxetine—Skin disorder—Estradiol—osteoporosis	0.000173	0.000401	CcSEcCtD
Duloxetine—Hyperhidrosis—Estradiol—osteoporosis	0.000172	0.000399	CcSEcCtD
Duloxetine—Rash—Ethinyl Estradiol—osteoporosis	0.000172	0.000399	CcSEcCtD
Duloxetine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000172	0.000399	CcSEcCtD
Duloxetine—Headache—Ethinyl Estradiol—osteoporosis	0.000171	0.000397	CcSEcCtD
Duloxetine—Hypersensitivity—Zoledronate—osteoporosis	0.000171	0.000395	CcSEcCtD
Duloxetine—Vomiting—Risedronate—osteoporosis	0.000169	0.000392	CcSEcCtD
Duloxetine—Rash—Risedronate—osteoporosis	0.000168	0.000389	CcSEcCtD
Duloxetine—Dermatitis—Risedronate—osteoporosis	0.000168	0.000389	CcSEcCtD
Duloxetine—Dizziness—Pamidronate—osteoporosis	0.000168	0.000388	CcSEcCtD
Duloxetine—Headache—Risedronate—osteoporosis	0.000167	0.000387	CcSEcCtD
Duloxetine—Asthenia—Zoledronate—osteoporosis	0.000166	0.000384	CcSEcCtD
Duloxetine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000164	0.00038	CcSEcCtD
Duloxetine—Pruritus—Zoledronate—osteoporosis	0.000164	0.000379	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000163	0.000376	CcSEcCtD
Duloxetine—Nausea—Ethinyl Estradiol—osteoporosis	0.000162	0.000376	CcSEcCtD
Duloxetine—Insomnia—Estradiol—osteoporosis	0.000161	0.000374	CcSEcCtD
Duloxetine—Vomiting—Pamidronate—osteoporosis	0.000161	0.000373	CcSEcCtD
Duloxetine—Paraesthesia—Estradiol—osteoporosis	0.00016	0.000371	CcSEcCtD
Duloxetine—Asthenia—Conjugated Estrogens—osteoporosis	0.00016	0.00037	CcSEcCtD
Duloxetine—Rash—Pamidronate—osteoporosis	0.00016	0.00037	CcSEcCtD
Duloxetine—Dermatitis—Pamidronate—osteoporosis	0.00016	0.00037	CcSEcCtD
Duloxetine—Headache—Pamidronate—osteoporosis	0.000159	0.000368	CcSEcCtD
Duloxetine—Somnolence—Estradiol—osteoporosis	0.000159	0.000367	CcSEcCtD
Duloxetine—Diarrhoea—Zoledronate—osteoporosis	0.000158	0.000367	CcSEcCtD
Duloxetine—Nausea—Risedronate—osteoporosis	0.000158	0.000367	CcSEcCtD
Duloxetine—Pruritus—Conjugated Estrogens—osteoporosis	0.000158	0.000365	CcSEcCtD
Duloxetine—Dyspepsia—Estradiol—osteoporosis	0.000157	0.000364	CcSEcCtD
Duloxetine—Decreased appetite—Estradiol—osteoporosis	0.000155	0.000359	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Estradiol—osteoporosis	0.000154	0.000357	CcSEcCtD
Duloxetine—Fatigue—Estradiol—osteoporosis	0.000154	0.000356	CcSEcCtD
Duloxetine—Dizziness—Zoledronate—osteoporosis	0.000153	0.000354	CcSEcCtD
Duloxetine—Constipation—Estradiol—osteoporosis	0.000153	0.000353	CcSEcCtD
Duloxetine—Pain—Estradiol—osteoporosis	0.000153	0.000353	CcSEcCtD
Duloxetine—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000153	0.000353	CcSEcCtD
Duloxetine—Nausea—Pamidronate—osteoporosis	0.000151	0.000348	CcSEcCtD
Duloxetine—Dizziness—Conjugated Estrogens—osteoporosis	0.000147	0.000341	CcSEcCtD
Duloxetine—Vomiting—Zoledronate—osteoporosis	0.000147	0.000341	CcSEcCtD
Duloxetine—Feeling abnormal—Estradiol—osteoporosis	0.000147	0.00034	CcSEcCtD
Duloxetine—Rash—Zoledronate—osteoporosis	0.000146	0.000338	CcSEcCtD
Duloxetine—Gastrointestinal pain—Estradiol—osteoporosis	0.000146	0.000338	CcSEcCtD
Duloxetine—Dermatitis—Zoledronate—osteoporosis	0.000146	0.000338	CcSEcCtD
Duloxetine—Headache—Zoledronate—osteoporosis	0.000145	0.000336	CcSEcCtD
Duloxetine—Vomiting—Conjugated Estrogens—osteoporosis	0.000142	0.000328	CcSEcCtD
Duloxetine—Urticaria—Estradiol—osteoporosis	0.000142	0.000328	CcSEcCtD
Duloxetine—Abdominal pain—Estradiol—osteoporosis	0.000141	0.000326	CcSEcCtD
Duloxetine—Body temperature increased—Estradiol—osteoporosis	0.000141	0.000326	CcSEcCtD
Duloxetine—Rash—Conjugated Estrogens—osteoporosis	0.000141	0.000325	CcSEcCtD
Duloxetine—Dermatitis—Conjugated Estrogens—osteoporosis	0.00014	0.000325	CcSEcCtD
Duloxetine—Headache—Conjugated Estrogens—osteoporosis	0.00014	0.000323	CcSEcCtD
Duloxetine—Nausea—Zoledronate—osteoporosis	0.000137	0.000318	CcSEcCtD
Duloxetine—Nausea—Conjugated Estrogens—osteoporosis	0.000132	0.000307	CcSEcCtD
Duloxetine—Hypersensitivity—Estradiol—osteoporosis	0.000131	0.000304	CcSEcCtD
Duloxetine—Asthenia—Estradiol—osteoporosis	0.000128	0.000296	CcSEcCtD
Duloxetine—Pruritus—Estradiol—osteoporosis	0.000126	0.000292	CcSEcCtD
Duloxetine—Diarrhoea—Estradiol—osteoporosis	0.000122	0.000283	CcSEcCtD
Duloxetine—Dizziness—Estradiol—osteoporosis	0.000118	0.000273	CcSEcCtD
Duloxetine—Vomiting—Estradiol—osteoporosis	0.000113	0.000263	CcSEcCtD
Duloxetine—Rash—Estradiol—osteoporosis	0.000112	0.00026	CcSEcCtD
Duloxetine—Dermatitis—Estradiol—osteoporosis	0.000112	0.00026	CcSEcCtD
Duloxetine—Headache—Estradiol—osteoporosis	0.000112	0.000259	CcSEcCtD
Duloxetine—Nausea—Estradiol—osteoporosis	0.000106	0.000245	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6R—osteoporosis	8.76e-05	0.00143	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—KL—osteoporosis	8.73e-05	0.00143	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CALCA—osteoporosis	8.62e-05	0.00141	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—POMC—osteoporosis	8.52e-05	0.00139	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PTHLH—osteoporosis	8.5e-05	0.00139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	8.37e-05	0.00137	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6R—osteoporosis	8.31e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTH—osteoporosis	8.23e-05	0.00135	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP19A1—osteoporosis	8.19e-05	0.00134	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—CYP19A1—osteoporosis	8.08e-05	0.00132	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	8.04e-05	0.00131	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—osteoporosis	8.03e-05	0.00131	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CNR2—osteoporosis	8.02e-05	0.00131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MGLL—osteoporosis	7.96e-05	0.0013	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.85e-05	0.00128	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	7.8e-05	0.00128	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—TGFB1—osteoporosis	7.8e-05	0.00127	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—WNT1—osteoporosis	7.54e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SOST—osteoporosis	7.54e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PTHLH—osteoporosis	7.51e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CALCA—osteoporosis	7.48e-05	0.00122	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MGLL—osteoporosis	7.36e-05	0.0012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LRP5—osteoporosis	7.18e-05	0.00117	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	6.94e-05	0.00113	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	6.92e-05	0.00113	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—TGFB1—osteoporosis	6.91e-05	0.00113	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	6.91e-05	0.00113	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LRP6—osteoporosis	6.87e-05	0.00112	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	6.84e-05	0.00112	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ADCY5—osteoporosis	6.84e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PTHLH—osteoporosis	6.82e-05	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALCR—osteoporosis	6.82e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTH1R—osteoporosis	6.82e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	6.77e-05	0.00111	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTH—osteoporosis	6.68e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—osteoporosis	6.66e-05	0.00109	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SPP1—osteoporosis	6.62e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CALCA—osteoporosis	6.61e-05	0.00108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOST—osteoporosis	6.55e-05	0.00107	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	6.51e-05	0.00106	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CNR2—osteoporosis	6.51e-05	0.00106	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—osteoporosis	6.48e-05	0.00106	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	6.45e-05	0.00105	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	6.45e-05	0.00105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	6.34e-05	0.00104	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—POMC—osteoporosis	6.12e-05	0.001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTH—osteoporosis	6.06e-05	0.000991	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CALCA—osteoporosis	6.01e-05	0.000982	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IRS2—osteoporosis	5.99e-05	0.000978	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	5.92e-05	0.000968	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALCR—osteoporosis	5.92e-05	0.000968	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTH1R—osteoporosis	5.92e-05	0.000968	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CNR2—osteoporosis	5.91e-05	0.000966	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.89e-05	0.000962	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—LEP—osteoporosis	5.86e-05	0.000957	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TLN1—osteoporosis	5.8e-05	0.000948	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTH—osteoporosis	5.8e-05	0.000948	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CNR2—osteoporosis	5.65e-05	0.000923	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—ESR1—osteoporosis	5.59e-05	0.000914	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—WNT1—osteoporosis	5.56e-05	0.000908	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PTHLH—osteoporosis	5.53e-05	0.000904	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MGLL—osteoporosis	5.42e-05	0.000885	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—osteoporosis	5.29e-05	0.000865	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LRP5—osteoporosis	5.29e-05	0.000864	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTH—osteoporosis	5.27e-05	0.000861	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IRS1—osteoporosis	5.23e-05	0.000854	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.22e-05	0.000852	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	5.14e-05	0.00084	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CNR2—osteoporosis	5.13e-05	0.000839	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	5.07e-05	0.000829	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LRP6—osteoporosis	5.06e-05	0.000826	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—POMC—osteoporosis	5.03e-05	0.000823	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTHLH—osteoporosis	5.02e-05	0.000821	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—P4HB—osteoporosis	5e-05	0.000817	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—POMC—osteoporosis	4.92e-05	0.000804	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6R—osteoporosis	4.91e-05	0.000802	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CALCA—osteoporosis	4.87e-05	0.000796	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTH—osteoporosis	4.86e-05	0.000795	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IGF1—osteoporosis	4.84e-05	0.000791	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—osteoporosis	4.83e-05	0.00079	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—WNT1—osteoporosis	4.82e-05	0.000788	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PTHLH—osteoporosis	4.8e-05	0.000785	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAP1A—osteoporosis	4.78e-05	0.000781	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CNR2—osteoporosis	4.74e-05	0.000775	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—ADCY5—osteoporosis	4.7e-05	0.000769	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MGLL—osteoporosis	4.7e-05	0.000769	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFATC1—osteoporosis	4.66e-05	0.000762	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FDPS—osteoporosis	4.64e-05	0.000759	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PKM—osteoporosis	4.64e-05	0.000759	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—DKK1—osteoporosis	4.63e-05	0.000756	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LRP5—osteoporosis	4.59e-05	0.00075	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—POMC—osteoporosis	4.51e-05	0.000737	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—WNT1—osteoporosis	4.46e-05	0.000728	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CALCA—osteoporosis	4.42e-05	0.000723	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPD2—osteoporosis	4.4e-05	0.000719	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PGLS—osteoporosis	4.4e-05	0.000719	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LRP6—osteoporosis	4.39e-05	0.000718	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTHLH—osteoporosis	4.36e-05	0.000713	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGA—osteoporosis	4.34e-05	0.000709	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.31e-05	0.000705	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—ADCY5—osteoporosis	4.27e-05	0.000698	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TLN1—osteoporosis	4.27e-05	0.000698	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CALCA—osteoporosis	4.23e-05	0.000691	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—POMC—osteoporosis	4.17e-05	0.000681	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTHLH—osteoporosis	4.03e-05	0.000659	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BMP2—osteoporosis	4.03e-05	0.000659	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ATIC—osteoporosis	4.02e-05	0.000658	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PNP—osteoporosis	4.02e-05	0.000658	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGB—osteoporosis	3.94e-05	0.000645	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PKM—osteoporosis	3.93e-05	0.000643	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FDPS—osteoporosis	3.93e-05	0.000643	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—POMC—osteoporosis	3.92e-05	0.00064	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—osteoporosis	3.9e-05	0.000637	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CALCA—osteoporosis	3.84e-05	0.000628	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSMA2—osteoporosis	3.81e-05	0.000622	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PSMA5—osteoporosis	3.81e-05	0.000622	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PGLS—osteoporosis	3.73e-05	0.000609	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPD2—osteoporosis	3.73e-05	0.000609	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TLN1—osteoporosis	3.71e-05	0.000606	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—osteoporosis	3.7e-05	0.000605	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—P4HB—osteoporosis	3.68e-05	0.000602	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTH—osteoporosis	3.58e-05	0.000585	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CALCA—osteoporosis	3.55e-05	0.00058	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAP1A—osteoporosis	3.52e-05	0.000575	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CNR2—osteoporosis	3.49e-05	0.00057	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.48e-05	0.000568	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—ADCY5—osteoporosis	3.46e-05	0.000566	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—POMC—osteoporosis	3.46e-05	0.000566	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFATC1—osteoporosis	3.43e-05	0.000561	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—OXCT1—osteoporosis	3.42e-05	0.000559	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CA2—osteoporosis	3.42e-05	0.000559	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ATIC—osteoporosis	3.41e-05	0.000557	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PNP—osteoporosis	3.41e-05	0.000557	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—DKK1—osteoporosis	3.41e-05	0.000557	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MGLL—osteoporosis	3.33e-05	0.000545	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—WNT1—osteoporosis	3.28e-05	0.000536	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KL—osteoporosis	3.22e-05	0.000527	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—P4HB—osteoporosis	3.2e-05	0.000523	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGA—osteoporosis	3.19e-05	0.000522	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—ADCY5—osteoporosis	3.15e-05	0.000514	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—POMC—osteoporosis	3.14e-05	0.000514	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTH—osteoporosis	3.11e-05	0.000508	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6R—osteoporosis	3.07e-05	0.000501	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAP1A—osteoporosis	3.06e-05	0.0005	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CNR2—osteoporosis	3.03e-05	0.000495	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	3.02e-05	0.000493	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—ADCY5—osteoporosis	3.01e-05	0.000492	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFATC1—osteoporosis	2.98e-05	0.000487	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTHLH—osteoporosis	2.97e-05	0.000485	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BMP2—osteoporosis	2.97e-05	0.000485	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DKK1—osteoporosis	2.96e-05	0.000484	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MYC—osteoporosis	2.91e-05	0.000475	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGB—osteoporosis	2.9e-05	0.000475	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—osteoporosis	2.9e-05	0.000474	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CA2—osteoporosis	2.9e-05	0.000474	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—OXCT1—osteoporosis	2.9e-05	0.000474	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—WNT1—osteoporosis	2.85e-05	0.000466	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IDH2—osteoporosis	2.84e-05	0.000463	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MGLL—osteoporosis	2.83e-05	0.000462	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSMA2—osteoporosis	2.8e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PSMA5—osteoporosis	2.8e-05	0.000458	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGA—osteoporosis	2.77e-05	0.000453	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—ADCY5—osteoporosis	2.73e-05	0.000447	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP27A1—osteoporosis	2.67e-05	0.000436	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.66e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALCA—osteoporosis	2.61e-05	0.000427	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ACP5—osteoporosis	2.59e-05	0.000424	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTHLH—osteoporosis	2.58e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BMP2—osteoporosis	2.58e-05	0.000421	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—POMC—osteoporosis	2.55e-05	0.000417	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ADCY5—osteoporosis	2.52e-05	0.000412	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGB—osteoporosis	2.52e-05	0.000412	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—osteoporosis	2.44e-05	0.000399	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSMA5—osteoporosis	2.43e-05	0.000398	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PSMA2—osteoporosis	2.43e-05	0.000398	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—TPI1—osteoporosis	2.41e-05	0.000394	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IDH2—osteoporosis	2.4e-05	0.000393	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KL—osteoporosis	2.37e-05	0.000388	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—POMC—osteoporosis	2.31e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALCA—osteoporosis	2.27e-05	0.000371	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—P4HB—osteoporosis	2.27e-05	0.00037	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP27A1—osteoporosis	2.26e-05	0.000369	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6R—osteoporosis	2.26e-05	0.000369	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GAPDH—osteoporosis	2.23e-05	0.000364	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—POMC—osteoporosis	2.21e-05	0.000362	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS2—osteoporosis	2.21e-05	0.000361	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ACP5—osteoporosis	2.2e-05	0.000359	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—osteoporosis	2.19e-05	0.000357	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.17e-05	0.000355	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—RAP1A—osteoporosis	2.17e-05	0.000354	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—osteoporosis	2.16e-05	0.000353	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—osteoporosis	2.06e-05	0.000337	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KL—osteoporosis	2.06e-05	0.000337	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—TPI1—osteoporosis	2.04e-05	0.000334	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—POMC—osteoporosis	2.01e-05	0.000328	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6R—osteoporosis	1.96e-05	0.00032	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS1—osteoporosis	1.93e-05	0.000315	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—P4HB—osteoporosis	1.92e-05	0.000314	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GAPDH—osteoporosis	1.88e-05	0.000308	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADCY5—osteoporosis	1.86e-05	0.000304	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—POMC—osteoporosis	1.86e-05	0.000303	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—RAP1A—osteoporosis	1.84e-05	0.0003	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6R—osteoporosis	1.81e-05	0.000296	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—osteoporosis	1.8e-05	0.000294	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—osteoporosis	1.79e-05	0.000292	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ENO1—osteoporosis	1.75e-05	0.000286	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMA2—osteoporosis	1.73e-05	0.000282	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMA5—osteoporosis	1.73e-05	0.000282	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—osteoporosis	1.63e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADCY5—osteoporosis	1.61e-05	0.000264	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.6e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—osteoporosis	1.59e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—osteoporosis	1.56e-05	0.000255	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—osteoporosis	1.52e-05	0.000248	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO1—osteoporosis	1.48e-05	0.000243	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMA5—osteoporosis	1.46e-05	0.000239	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMA2—osteoporosis	1.46e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—osteoporosis	1.42e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—osteoporosis	1.41e-05	0.000231	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.4e-05	0.000229	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—osteoporosis	1.38e-05	0.000226	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—POMC—osteoporosis	1.37e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—osteoporosis	1.37e-05	0.000223	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6R—osteoporosis	1.33e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—osteoporosis	1.32e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—osteoporosis	1.31e-05	0.000215	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—osteoporosis	1.23e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—POMC—osteoporosis	1.19e-05	0.000194	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP19A1—osteoporosis	1.19e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6R—osteoporosis	1.16e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADCY5—osteoporosis	1.14e-05	0.000187	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—osteoporosis	1.14e-05	0.000187	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—osteoporosis	1.14e-05	0.000186	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—osteoporosis	1.07e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—osteoporosis	1.07e-05	0.000175	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—osteoporosis	1.05e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—osteoporosis	1.01e-05	0.000164	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADCY5—osteoporosis	9.69e-06	0.000158	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—osteoporosis	9.66e-06	0.000158	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—osteoporosis	8.92e-06	0.000146	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—osteoporosis	8.73e-06	0.000143	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—POMC—osteoporosis	8.42e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—osteoporosis	8.07e-06	0.000132	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—osteoporosis	7.9e-06	0.000129	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—osteoporosis	7.88e-06	0.000129	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—POMC—osteoporosis	7.13e-06	0.000117	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—osteoporosis	6.86e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—osteoporosis	6.85e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—osteoporosis	5.94e-06	9.71e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—osteoporosis	5.16e-06	8.43e-05	CbGpPWpGaD
